Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
Recruiting · Phase 2 · NCT07048262
Conditions: Non-cystic Fibrosis Bronchiectasis
At a glance
- Research payments reported, 2025
- $199,713
- U.S. investigators named
- 12
- Sites paid
- 11
- Planned or actual enrollment
- 180
About the trial
- Sponsor
- CSL Behring
- Tested
- CSL787 (biological), Placebo (drug), Nebulizer (device)
- Dates
- Started 2025-09-03; completion 2029-06-06
- Results posted
- Not yet
This study is a proof-of-concept phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose selection study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (human normal immunoglobulin G \[IgG\] inhalation solution) compared with placebo over 52 weeks. The primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 active treatment regimens of inhaled CSL787 administered to participants with NCFB toward prolonging the time to first (TTF) exacerbation.
From ClinicalTrials.gov, last updated 2026-10-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $199,713 in research payments for this study in 2025 (51 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lawrence J. Sindel, MD Allergy & Immunology · Mobile, AL
- Muhammad M. Salim, MD Pulmonology · Chandler, AZ
- Vikas Sayal, M.D. Pulmonology · Bullhead City, AZ
- Mircea O. Badara, M.D. Pulmonology · Stuart, FL
- Lisette Delgado Sanchez, MD Pulmonology · Naples, FL
- Ramses Vega, M.D. Internal Medicine · Miami, FL
- Colin Swenson, M.D. Pulmonology · Atlanta, GA
- Douglas B. Hornick, MD Pulmonology · Iowa City, IA
- Andreas Schmid, MD Pulmonology · Kansas City, KS
- Luis De La Cruz, MD Sleep Medicine · Spartanburg, SC
- Gustavo H. Day, M.D. Internal Medicine · Dallas, TX
- Carlo M. Hatem, MD Critical Care Medicine · El Paso, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research, Inc. $47,834
- Elligo Health Research, Inc $41,236
- Kumc Research Institute, Inc. $24,622
- Innovo Research $21,000
- Essence MD Research LLC $17,124
- Reliant Medical Research LLC $16,862
- Henderson Clinical Trials $14,000
- Chandler Clinical Research Trials LLC $14,000
- Elite Medical Research LLC $1,012
- Emory University Hospital, GA $1,012
- University of Chicago Medical Center $1,012
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.